SE0102067D0 - Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation - Google Patents

Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation

Info

Publication number
SE0102067D0
SE0102067D0 SE0102067A SE0102067A SE0102067D0 SE 0102067 D0 SE0102067 D0 SE 0102067D0 SE 0102067 A SE0102067 A SE 0102067A SE 0102067 A SE0102067 A SE 0102067A SE 0102067 D0 SE0102067 D0 SE 0102067D0
Authority
SE
Sweden
Prior art keywords
neovascularization
prevention
intervertebral discs
tissues
local inflammation
Prior art date
Application number
SE0102067A
Other languages
Swedish (sv)
Inventor
Kjell Olmarker
Original Assignee
A & Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & Science Invest Ab filed Critical A & Science Invest Ab
Priority to SE0102067A priority Critical patent/SE0102067D0/en
Publication of SE0102067D0 publication Critical patent/SE0102067D0/en
Priority to PCT/SE2002/001115 priority patent/WO2002100387A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The use of an anti-angiogenetic substance for the production of a pharmaceutical preparation for prevention of neovascularization and/or neoinnervation of intervertebral discs and/or of tissues with local inflammation, in particular for prevention of chronic pain, such as chronic low back pain and chronic whiplash associated disorder, is disclosed. Said neovascularization and/or neoinnervation of intervertebral discs may be caused by spinal trauma. Also a method for prevention of neovascularization and/or neoinnervation of intervertebral discs and/or of tissues with local inflammation wherein a therapeutically effective amount of an anti-angiogenetic substance is administered to an individual is disclosed.
SE0102067A 2001-06-11 2001-06-11 Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation SE0102067D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0102067A SE0102067D0 (en) 2001-06-11 2001-06-11 Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation
PCT/SE2002/001115 WO2002100387A1 (en) 2001-06-11 2002-06-10 Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102067A SE0102067D0 (en) 2001-06-11 2001-06-11 Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation

Publications (1)

Publication Number Publication Date
SE0102067D0 true SE0102067D0 (en) 2001-06-11

Family

ID=20284441

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102067A SE0102067D0 (en) 2001-06-11 2001-06-11 Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation

Country Status (2)

Country Link
SE (1) SE0102067D0 (en)
WO (1) WO2002100387A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491129A1 (en) * 2002-07-03 2004-01-15 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
EP2286804A1 (en) 2003-05-13 2011-02-23 DePuy Spine, Inc. A method of treating degenerative disc disease
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
US7217425B2 (en) 2004-07-23 2007-05-15 Depuy Spine, Inc. Autologous coatings for implants
US7399742B2 (en) 2004-07-23 2008-07-15 Depuy Spine, Inc. Anti-osteolytic therapy involving adiponectin
US8715733B2 (en) 2004-07-23 2014-05-06 DePuy Synthes Products, LLC Enhanced adipose tissue
ITRM20050290A1 (en) 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
EP3381471B1 (en) * 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
WO2010089387A1 (en) 2009-02-09 2010-08-12 Morphosys Ag Production of oligoclonal mixtures of immunoglobulins in single cells
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
CN110613837A (en) * 2019-10-24 2019-12-27 内蒙古医科大学第二附属医院 Application of TGF-beta in preparation of medicine for preventing or treating lumbar disc herniation

Also Published As

Publication number Publication date
WO2002100387A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
SE0102067D0 (en) Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation
MXPA05008617A (en) Uses of anti-insulin-like growth factor i receptor antibodies.
AU2003301190A1 (en) Administration of capsaicinoids
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
RS52867B (en) Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EA201170018A1 (en) Razagilin to change the flow of Parkinson's disease
ATE454140T1 (en) DOPAMINE AGONIST COMBINATION THERAPY WITH SEDATIVES TO IMPROVE SLEEP QUALITY
WO2006058140A3 (en) Capsaicinoid gel formulation and uses thereof
MY145790A (en) Composition
DE60321929D1 (en) PHARMACEUTICAL COMPOSITIONS WITH DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES
DK1965797T3 (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
BRPI0410721A (en) foamable pharmaceutical compositions and methods for treating a disorder
TW200635598A (en) Oral suspension comprising meloxicam
WO2003073981A3 (en) Novel of cytokine inhibitors
MXPA02009794A (en) Compositions for promoting sleep.
ZA200206696B (en) Viscoelastics for use in middle ear surgery.
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
HUP0100539A2 (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
WO2001089536A3 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
MXPA02006511A (en) Complex comprising ocif and polysaccharide.
SE0101256D0 (en) Treatment of low back pain
WO2005016381A3 (en) Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
DE60008293D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A NO DONOR AND ITS THERAPEUTIC USE